MedPath

Cholestyramine

Cholestyramine for Oral Suspension, USP

Approved
Approval ID

06261db5-1435-4b91-8b54-71bfcfb1368c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 12, 2021

Manufacturers
FDA

TAGI Pharma, Inc.

DUNS: 963322560

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cholestyramine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51224-011
Application NumberANDA209597
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cholestyramine
Product Specifications
Route of AdministrationORAL
Effective DateMay 12, 2021
FDA Product Classification

INGREDIENTS (8)

CholestyramineActive
Quantity: 4 g in 8.3 g
Code: 4B33BGI082
Classification: ACTIB
sucroseInactive
Code: C151H8M554
Classification: IACT
propylene glycol alginateInactive
Code: 26CD3J2R0C
Classification: IACT
orangeInactive
Code: 5EVU04N5QU
Classification: IACT
D&C YELLOW NO. 10 ALUMINUM LAKEInactive
Code: CQ3XH3DET6
Classification: IACT
anhydrous citric acidInactive
Code: XF417D3PSL
Classification: IACT
FD&C Yellow No. 6Inactive
Code: H77VEI93A8
Classification: IACT
aluminum oxideInactive
Code: LMI26O6933
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cholestyramine - FDA Drug Approval Details